Navigation Links
XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
Date:10/22/2007

ificity about their questions and the potential impact, if any, on our timeline, we will provide an update."

The company is also reiterating guidance that it expects to commercialize Custom NX in Europe in the second half of 2008.

About the CUSTOM Trials

The CUSTOM I trial is a 30-patient first-in-man study designed to evaluate the preliminary safety and feasibility of in-situ stent customization. CUSTOM I's positive eight-month clinical results have been sustained at two years with no new MACE events, zero restenosis and no late stent thrombosis.

The CUSTOM II trial is a 100-patient study designed to evaluate the safety and efficacy of Custom NX for the treatment of long and multiple lesions. Of the 100 patients enrolled, 69 patients were enrolled in the long-lesion arm, and 31 patients were enrolled in the two-lesion arm of the study. CUSTOM II enrolled one of the most difficult to treat patient populations ever studied in a DES trial. In the CUSTOM II patient population, the average vessel diameter was 2.57mm and the average lesion length was 28.7mm. Twenty-six percent of the study participants were diabetic. The percentage of patients with ACC/AHA lesion grade B2 or C was 65.1 percent. CUSTOM II's six-month clinical results have been sustained at one year. The target lesion revascularization rate remained constant at four percent, with no new MACE events, and no late stent thrombosis.

The company's CUSTOM III clinical trial completed enrollment in July as previously announced, and the company expects the first available data to be presented at the 2008 Euro-PCR meeting.

About the Custom NX(R) DES System

Custom NX is designed to enable a more personalized approach to the treatment of arterial disease based on each patient's individual lesion characteristics. The Custom NX system allows physicians to customize the length and diameter of the stent at the site of the lesion. The system features a proprietary modular stent de
'/>"/>

SOURCE XTENT, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. XTENT Announces Promising Six-Month Custom II Trial Data Presented at EuroPCR Meeting
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... UNICANCER pourra identifier ... bénéficier de l,innovation thérapeutique.   ... contenu pour l,Entreprise, annonce que sa solution Luxid® ... de lutte contre le cancer (CLCC), comme module ... (Continuum Soin-Recherche) conduit par la société de conseil ...
(Date:3/5/2015)... , March 5, 2015 BioLineRx ... clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and ... has commenced an underwritten public offering of American ... its Ordinary Shares. All of the ADSs in ... JMP Securities is acting as ...
(Date:3/5/2015)... SHANGHAI, March 5, 2015 WuXi PharmaTech (Cayman) ... R&D capability and technology platform company serving the pharmaceutical, ... and the United States, today announced its financial results ... Fourth-Quarter 2014 Highlights , Net Revenues ... , Laboratory Services Net Revenues Grew 17.7% Year Over ...
Breaking Medicine Technology:TEMIS et SWORD accompagnent UNICANCER pour accélérer la recherche par l'analyse sémantique des dossiers patients 2TEMIS et SWORD accompagnent UNICANCER pour accélérer la recherche par l'analyse sémantique des dossiers patients 3TEMIS et SWORD accompagnent UNICANCER pour accélérer la recherche par l'analyse sémantique des dossiers patients 4BioLineRx Announces Underwritten Public Offering of its American Depositary Shares 2BioLineRx Announces Underwritten Public Offering of its American Depositary Shares 3WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 2WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 3WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 4WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 5WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 6WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 7WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 8WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 9WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 10WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 11WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 12WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 13WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 14WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 15WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 16WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 17WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 18WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 19WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 20WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 21WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 22
... Show -- LifePort Inc. today announced the ... into customized mission-specific seating. LifePort is a Sikorsky ... of Sikorsky Aircraft Corp., a subsidiary of United ... http://photos.prnewswire.com/prnh/20080904/NETH086LOGO ) (Logo:   http://www.newscom.com/cgi-bin/prnh/20080904/NETH086LOGO ) ...
... Perrigo Company (Nasdaq: PRGO ; TASE) today announced ... fiscal 2011 on Tuesday, November 2, 2010 at approximately 8:00 ... 10:00 a.m. (ET) hosted by Joseph C. Papa, Perrigo,s Chairman ... be available live via webcast to interested parties on the ...
Cached Medicine Technology:LifePort Inc. Signs Two Agreements Launching Company Into Mission-Specific Seating 2
(Date:3/6/2015)... Jose, California (PRWEB) March 06, 2015 ... also known as the pharmacokinetics of a drug refers ... a pharmaceutical compound inside an organism. When toxicity studies ... ADME-Tox or ADMET or ADME/Tox. Increasing focus on lowering ... adoption of ADME-toxicology testing worldwide. The traditional drug development ...
(Date:3/6/2015)... NY (PRWEB) March 06, 2015 Ticket Down ... . This popular ticket exchange has extended their customer appreciation ... from Hebden Bridge, West Yorkshire England and he began his ... In the past couple of years Ed Sheeran has ... whenever Ed Sheeran is on stage he is having the ...
(Date:3/6/2015)... CA (PRWEB) March 06, 2015 US ... of three Maryland camps – two non-contact specialty camps ... be run by Perfect Performance Training, located at Bowie ... focus on developing position specific skills, speed and strength ... hosted at Salisbury University with Marvin Graves, former quarterback ...
(Date:3/6/2015)... As the Association of American Medical Colleges' ... by 2025 is updated this week and debated in ... preparing by analyzing demographics and pursuing viable solutions for ... factors including the increasing number of retiring doctors, increasing ... Care Act and an uneven distribution of new doctors ...
(Date:3/6/2015)... 2015 First Choice Emergency Room ... facility is located at 13351 W. Bowles Avenue, Littleton, Colorado ... is ready 24-7 to provide the highest quality emergency medical ... Director of First Choice Emergency Room Littleton. , ... South Metro Denver Chamber of Commerce and a medical community ...
Breaking Medicine News(10 mins):Health News:Growing Need to Reduce Drug Development Costs Drives the Global ADME-Toxicology Testing Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Growing Need to Reduce Drug Development Costs Drives the Global ADME-Toxicology Testing Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:Ed Sheeran Tickets in Indianapolis, Austin, Albany, St. Louis, London, Des Moines, Salt Lake City, Saskatoon, Regina and Denver/Morrison Now On Sale at Ticket Down 2Health News:US Sports Camps to Host Three New Football Camps in Maryland 2Health News:Susquehanna Health Plans Progressively to Prevent Projected Physician Shortfall 2Health News:Susquehanna Health Plans Progressively to Prevent Projected Physician Shortfall 3Health News:Susquehanna Health Plans Progressively to Prevent Projected Physician Shortfall 4Health News:First Choice Emergency Room Opens New Facility in Littleton, Colorado 2
... In international study has found that people in their ... five years longer than those with hypertension or high ... had normal blood pressure developed heart disease later in ... has been published in the current issue of Hypertension: ...
... research had showed that patients who are depressed and ... having another heart attack is lessened considerably with the ... often treat clinical depression, also known as unipolar depression, ... SSRIs are a group of drugs that can increase ...
... have less back pain from osteoporosis related// curving of the ... special exercises. ,In a study presented by the researchers ... back support device can not only decrease the back pain ... women who had suffered the disease. ,Elderly population remains ...
... by the ‘Delhi High Court’ on Tuesday Justice Vikramjit Sen passed ... 12 year old for the wrong treatment administered by Dr ... the next few days how much compensation was the hospital ready ... indicated that the operation for total hip replacement and fixation of ...
... from Children's Hospital Boston suggests that a urine test ... anomalies. The study also raises the possibility of treating ... of the journal - Pediatrics, has published an article ... found in about 10% of newly born infants and ...
... who have television in their bedroom may score less in ... TV in their rooms. In a new study by the ... Stanford University researchers have reported that the home environment, especially ... their ability to affect the performance of children in school. ...
Cached Medicine News:Health News:Normal Blood Pressure Could Add Over 5 Years To Your Life 2Health News:Simple Urine Test Can Help To Monitor Disfiguring Birthmarks, 2
The ideal on-the-spot reference for residents and practitioners seeking fast facts on fracture management....
5mSports™ is the handheld version of 5 Minute Sports Medicine Consult, your favorite reference for on-field and off-field treatment of sports related problems....
... all those involved with healthcare decisions to ... latest evidence in their field of interest ... year as the volume of evidence increases. ... the best single source available for continually ...
... on-the-spot reference guide for ... On the wards, in ... or at the bedside, ... access to reliable, clinically ...
Medicine Products: